Juan E Hernández-Ávila1, Lina S Palacio-Mejía, Alfonso Hernández-Romieu, Sergio Bautista-Arredondo, Jaime Sepúlveda Amor, Mauricio Hernández-Ávila. 1. *Centro de Información para Decisiones en Salud Pública, Instituto Nacional de Salud Pública, Cuernavaca, México; †Department of Epidemiology, Emory University, Atlanta, GA; ‡Global Health Sciences, University of California (UC) San Francisco, San Francisco, CA, USA and Emeritus Professor of Public Health, National Institute of Public Health, Mexico; **Centro de Investigación en Sistemas de Salud. Instituto Nacional de Salud Pública México; and ††Dirección General. Instituto Nacional de Salud Pública.
Abstract
INTRODUCTION: Universal coverage of highly active antiretroviral therapy (HAART) for HIV/AIDS in Mexico was achieved in a staggered fashion. First, HAART was made available in 1997 for employees in the formal sector and subsequently, in 2003, for informal sector workers and the unemployed population. We evaluated the impact of this free universal HAART program on HIV/AIDS mortality in the Mexican population aged 15 years or older. METHODS: Time-series cross-sectional data analysis of standardized HIV/AIDS mortality rates (1990-2011) using marginal linear models with inflection points at 1994, 1997, and 2003. RESULTS: Men employed in the formal sector experienced the greatest effect of access to HAART, with a 32% reduction in mortality from 1997 to 2011 (P < 0.01). For men in this sector, mortality increased from 1990 to 2003, then stabilizing at 7 deaths per 100,000. For women in the informal sector, mortality increased from 1990 to 2011. We found large between-state variability: mortality decreased by 59% in Mexico City while it increased by 245% in Tabasco during the study period. Six of 32 states achieved statistically significant reductions in mortality while 5 states continued to experience increasing mortality rates despite universal HAART. CONCLUSIONS: Access to universal HAART has had relative success in Mexico. The heterogeneity of HIV/AIDS mortality by employment status, gender, and state of residence highlight urgent needs to improve health equity with pro-poor and gender-responsive programs and a call for country-specific operational research in HIV/AIDS prevention and treatment. Our results may apply to other countries seeking to implement universal access to antiretroviral therapy.
INTRODUCTION: Universal coverage of highly active antiretroviral therapy (HAART) for HIV/AIDS in Mexico was achieved in a staggered fashion. First, HAART was made available in 1997 for employees in the formal sector and subsequently, in 2003, for informal sector workers and the unemployed population. We evaluated the impact of this free universal HAART program on HIV/AIDS mortality in the Mexican population aged 15 years or older. METHODS: Time-series cross-sectional data analysis of standardized HIV/AIDS mortality rates (1990-2011) using marginal linear models with inflection points at 1994, 1997, and 2003. RESULTS:Men employed in the formal sector experienced the greatest effect of access to HAART, with a 32% reduction in mortality from 1997 to 2011 (P < 0.01). For men in this sector, mortality increased from 1990 to 2003, then stabilizing at 7 deaths per 100,000. For women in the informal sector, mortality increased from 1990 to 2011. We found large between-state variability: mortality decreased by 59% in Mexico City while it increased by 245% in Tabasco during the study period. Six of 32 states achieved statistically significant reductions in mortality while 5 states continued to experience increasing mortality rates despite universal HAART. CONCLUSIONS: Access to universal HAART has had relative success in Mexico. The heterogeneity of HIV/AIDS mortality by employment status, gender, and state of residence highlight urgent needs to improve health equity with pro-poor and gender-responsive programs and a call for country-specific operational research in HIV/AIDS prevention and treatment. Our results may apply to other countries seeking to implement universal access to antiretroviral therapy.
Authors: Thomas Engell-Sørensen; Andreas Rieckmann; Candida Medina; David da Silva Té; Amabelia Rodrigues; Ane Bærent Fisker; Peter Aaby; Christian Erikstrup; Sanne Jespersen; Christian Wejse; Bo Langhoff Hønge Journal: Infection Date: 2021-02-02 Impact factor: 3.553
Authors: Pablo F Belaunzarán-Zamudio; Yanink N Caro-Vega; Bryan E Shepherd; Peter F Rebeiro; Brenda E Crabtree-Ramírez; Claudia P Cortes; Beatriz Grinsztejn; Eduardo Gotuzzo; Fernando Mejia; Denis Padgett; Jean W Pape; Vanessa Rouzier; Valdilea Veloso; Sandra Wagner Cardoso; Catherine C McGowan; Juan G Sierra-Madero Journal: Am J Epidemiol Date: 2020-06-01 Impact factor: 4.897
Authors: Jose L Burgos; Thomas L Patterson; Joshua S Graff-Zivin; James G Kahn; M Gudelia Rangel; M Remedios Lozada; Hugo Staines; Steffanie A Strathdee Journal: PLoS One Date: 2016-02-18 Impact factor: 3.752
Authors: Eileen V Pitpitan; Shirley J Semple; Gregory A Aarons; Lawrence A Palinkas; Claudia V Chavarin; Doroteo V Mendoza; Carlos Magis-Rodriguez; Hugo Staines; Thomas L Patterson Journal: PLoS One Date: 2018-09-11 Impact factor: 3.240
Authors: S Jespersen; F Månsson; J Lindman; C Wejse; C Medina; Z J da Silva; DdS Te; P Medstrand; J Esbjörnsson; B L Hønge Journal: AIDS Res Ther Date: 2020-02-04 Impact factor: 2.250